JPWO2021191803A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021191803A5 JPWO2021191803A5 JP2022557708A JP2022557708A JPWO2021191803A5 JP WO2021191803 A5 JPWO2021191803 A5 JP WO2021191803A5 JP 2022557708 A JP2022557708 A JP 2022557708A JP 2022557708 A JP2022557708 A JP 2022557708A JP WO2021191803 A5 JPWO2021191803 A5 JP WO2021191803A5
- Authority
- JP
- Japan
- Prior art keywords
- clathrate
- weight
- optionally
- amount
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 35
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 32
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 24
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims 24
- BQOFWKZOCNGFEC-UHFFFAOYSA-N carene Chemical compound C1C(C)=CCC2C(C)(C)C12 BQOFWKZOCNGFEC-UHFFFAOYSA-N 0.000 claims 24
- 238000009472 formulation Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 13
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims 12
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims 12
- 229930006739 camphene Natural products 0.000 claims 12
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims 12
- TWVJWDMOZJXUID-QJPTWQEYSA-N guaiol Natural products OC(C)(C)[C@H]1CC=2[C@H](C)CCC=2[C@@H](C)CC1 TWVJWDMOZJXUID-QJPTWQEYSA-N 0.000 claims 12
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 11
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 11
- TWVJWDMOZJXUID-SDDRHHMPSA-N Guaiol Chemical compound C1([C@H](CC[C@H](C2)C(C)(C)O)C)=C2[C@@H](C)CC1 TWVJWDMOZJXUID-SDDRHHMPSA-N 0.000 claims 11
- 229960005233 cineole Drugs 0.000 claims 11
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims 9
- 235000019477 peppermint oil Nutrition 0.000 claims 9
- 239000003921 oil Substances 0.000 claims 7
- 235000019198 oils Nutrition 0.000 claims 7
- 239000004382 Amylase Substances 0.000 claims 6
- 108010065511 Amylases Proteins 0.000 claims 6
- 102000013142 Amylases Human genes 0.000 claims 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims 6
- 235000019418 amylase Nutrition 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 235000020765 fenugreek extract Nutrition 0.000 claims 6
- 244000250129 Trigonella foenum graecum Species 0.000 claims 5
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims 5
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 244000166124 Eucalyptus globulus Species 0.000 claims 3
- 244000246386 Mentha pulegium Species 0.000 claims 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims 3
- 241001479543 Mentha x piperita Species 0.000 claims 3
- 241000219926 Myrtaceae Species 0.000 claims 3
- 241000779819 Syncarpia glomulifera Species 0.000 claims 3
- HIAAVKYLDRCDFQ-UHFFFAOYSA-L calcium;dodecanoate Chemical compound [Ca+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O HIAAVKYLDRCDFQ-UHFFFAOYSA-L 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 235000001050 hortel pimenta Nutrition 0.000 claims 3
- 239000001771 mentha piperita Substances 0.000 claims 3
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 235000005205 Pinus Nutrition 0.000 claims 2
- 241000218602 Pinus <genus> Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 201000009267 bronchiectasis Diseases 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 claims 2
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 235000012570 Pinus sp Nutrition 0.000 claims 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 108010032220 cyclomaltodextrinase Proteins 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 claims 1
- 125000001538 guaiol group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108010035855 neopullulanase Proteins 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000001917 trigonella foenum graecum l. absolute Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993346P | 2020-03-23 | 2020-03-23 | |
| US62/993,346 | 2020-03-23 | ||
| PCT/IB2021/052411 WO2021191803A1 (en) | 2020-03-23 | 2021-03-23 | Oral terpene cyclodextrin inclusion complex vehicles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519232A JP2023519232A (ja) | 2023-05-10 |
| JPWO2021191803A5 true JPWO2021191803A5 (zh) | 2024-03-15 |
Family
ID=77890198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557708A Pending JP2023519232A (ja) | 2020-03-23 | 2021-03-23 | 経口テルペンシクロデキストリン包接体ビヒクル |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230142208A1 (zh) |
| EP (1) | EP4125830A4 (zh) |
| JP (1) | JP2023519232A (zh) |
| KR (1) | KR20220156931A (zh) |
| CN (1) | CN115335040A (zh) |
| AU (1) | AU2021240473A1 (zh) |
| BR (1) | BR112022019223A2 (zh) |
| CA (1) | CA3170465A1 (zh) |
| IL (1) | IL296661A (zh) |
| WO (1) | WO2021191803A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023012552A1 (en) * | 2021-08-04 | 2023-02-09 | Czap Research And Development, Llc | Anandamide cyclodextrin inclusion complex vehicles |
| CN116270589B (zh) * | 2023-02-08 | 2024-05-31 | 北京奥秘佳得医药科技有限公司 | 药物组合物和化合物在制备用于治疗疾病的药物中的用途 |
| CN117357556B (zh) * | 2023-11-06 | 2024-04-19 | 广州市生基科技有限公司 | 一种高稳定性的氧胶囊的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| DK1556021T3 (da) * | 2002-10-24 | 2008-04-28 | Immupharm As | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger |
| JP4787240B2 (ja) * | 2004-04-01 | 2011-10-05 | ユニベルシテ・ド・リエージュ | ピリミジン−２，４，６−トリオンのシクロデキストリン包接複合体 |
| US20060120967A1 (en) * | 2004-12-07 | 2006-06-08 | Qpharma, Llc | Solution forms of cyclodextrins for nasal or throat delivery of essential oils |
| US20100184722A1 (en) * | 2008-12-19 | 2010-07-22 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
| KR101050429B1 (ko) * | 2009-03-18 | 2011-07-19 | 연세대학교 산학협력단 | 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 |
| US10098964B2 (en) * | 2015-03-12 | 2018-10-16 | The Board Of Trustees Of The University Of Illinois | Inclusion complexes and methods for making the same |
| RS62097B1 (sr) * | 2016-02-04 | 2021-08-31 | Czap Research And Development Llc | Pomoćna farmaceutska sredstva sa kontrolisanim otpuštanjem i raslojeni kompleks koji uključuje ciklodekstrin |
| US20170224841A1 (en) * | 2016-02-04 | 2017-08-10 | Czap Reseach And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
| US20170224842A1 (en) * | 2016-02-04 | 2017-08-10 | Czap Research And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
| US10058531B1 (en) * | 2017-06-01 | 2018-08-28 | Spartak LLC | Dosage delivery film |
| WO2020012315A1 (en) * | 2018-07-08 | 2020-01-16 | Buzzelet Development And Technologies Ltd. | Terpene-enriched cannabinoid composition for treatment of male subjects |
| WO2020168421A1 (en) * | 2019-02-19 | 2020-08-27 | Agrima Scientific Corp. | Cyclodextrin inclusion complexes of cannabis extracts |
-
2021
- 2021-03-23 BR BR112022019223A patent/BR112022019223A2/pt unknown
- 2021-03-23 CA CA3170465A patent/CA3170465A1/en active Pending
- 2021-03-23 CN CN202180023966.5A patent/CN115335040A/zh active Pending
- 2021-03-23 IL IL296661A patent/IL296661A/en unknown
- 2021-03-23 JP JP2022557708A patent/JP2023519232A/ja active Pending
- 2021-03-23 KR KR1020227036822A patent/KR20220156931A/ko active Search and Examination
- 2021-03-23 AU AU2021240473A patent/AU2021240473A1/en active Pending
- 2021-03-23 EP EP21774359.0A patent/EP4125830A4/en active Pending
- 2021-03-23 WO PCT/IB2021/052411 patent/WO2021191803A1/en active Application Filing
- 2021-03-23 US US17/906,512 patent/US20230142208A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1991201B1 (en) | Nebulised antibiotics for inhalation therapy | |
| DK1732512T3 (en) | INHALABLE FORMULATION CONTAINING SULPHALKYLETHERCYCLODEXTRIN AND CORTIC COSTEROID | |
| Lachowicz et al. | Characteristic of Cyclodextrins: Their role and use in the pharmaceutical technology | |
| WO2008005691A1 (en) | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension | |
| US20060120967A1 (en) | Solution forms of cyclodextrins for nasal or throat delivery of essential oils | |
| JP5254618B2 (ja) | 経鼻投与用組成物 | |
| RU2607592C2 (ru) | Новая фармацевтическая композиция, включающая нпвс и циклодекстрин | |
| US7141555B2 (en) | Modafinil compound and cyclodextrin mixtures | |
| JP2013523860A (ja) | Ｈｒｔのための極低用量固体経口投与形態 | |
| EP2043599A1 (en) | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
| JP3693341B2 (ja) | タキソールまたはタキソテレまたはイチイ抽出物と、シクロデキストリンとから成る封入複合体、該複合体の製造及び使用 | |
| CN110237260A (zh) | 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 | |
| JP2023519232A (ja) | 経口テルペンシクロデキストリン包接体ビヒクル | |
| JPWO2021191803A5 (zh) | ||
| JP2022520990A (ja) | 呼吸器疾患の治療の方法 | |
| CN115671291A (zh) | 一种基于g型褐藻寡糖的雾化剂、雾化剂浓缩液及其制备方法和应用 | |
| JP7138643B2 (ja) | 水溶性フォルスコリンの新規製造法 | |
| KR100807480B1 (ko) | 피리베딜의 경비 투여용 약제 조성물 | |
| WO2024117984A1 (en) | Water-soluble cannabidiol compositions and method for preparation of water-soluble cannabidiol | |
| WO2021249578A2 (zh) | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 | |
| WO2022144835A1 (en) | Usnic acid, or inclusion complexes thereof, for use in the treatment of infections with a coronavirus or bacteria | |
| CN118121747A (zh) | 一种海藻多糖雾化剂液体敷料及其制备方法 | |
| Murris-Espin et al. | L’azithromycine est efficace à court terme au cours de la mucoviscidose chez les patients colonisés chroniques à Pseudomonas aeruginosa| Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomised controlled trial, L. Saiman, BC Marshall, N. Mayer-Hamblett, J. Burns, AL Quittner, DA Cibene, S. Coquillette, AY Fieberg, FJ Accurso, PW Campbell, in: JAMA, 290 (2003), pp. 1749-1756 | |
| JP2020503356A5 (zh) |